相似文献
1
Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent.
Drug Deliv Transl Res. 2021 Apr;11(2):692-701. doi: 10.1007/s13346-021-00927-4. Epub 2021 Feb 15.
2
Long-term stability of influenza vaccine in a dissolving microneedle patch.
Drug Deliv Transl Res. 2017 Apr;7(2):195-205. doi: 10.1007/s13346-016-0282-2.
3
Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches.
Pharm Res. 2016 Apr;33(4):868-78. doi: 10.1007/s11095-015-1833-9. Epub 2015 Dec 1.
4
Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.
Clin Vaccine Immunol. 2013 Sep;20(9):1433-9. doi: 10.1128/CVI.00251-13. Epub 2013 Jul 17.
5
Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
Drug Deliv Transl Res. 2015 Aug;5(4):360-71. doi: 10.1007/s13346-015-0228-0.
6
Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch.
AAPS PharmSciTech. 2021 Jun 10;22(5):175. doi: 10.1208/s12249-021-02044-4.
7
Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
J Control Release. 2015 Jul 28;210:208-16. doi: 10.1016/j.jconrel.2015.05.278. Epub 2015 May 21.
8
A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
J Control Release. 2017 Sep 10;261:1-9. doi: 10.1016/j.jconrel.2017.06.017. Epub 2017 Jun 19.
9
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
J Pharm Sci. 2012 Mar;101(3):1021-7. doi: 10.1002/jps.23019. Epub 2011 Dec 20.
10
Development of a thermostable microneedle patch for influenza vaccination.
J Pharm Sci. 2015 Feb;104(2):740-9. doi: 10.1002/jps.24283. Epub 2014 Dec 1.
引用本文的文献
1
Fabrication of porous polymeric microneedles: a concise overview.
RSC Adv. 2025 Jun 4;15(23):18697-18714. doi: 10.1039/d5ra03274a. eCollection 2025 May 29.
2
Multi-Layered Microneedles Loaded with Microspheres.
AAPS PharmSciTech. 2025 Jan 3;26(1):19. doi: 10.1208/s12249-024-03016-0.
3
Exploiting Unique Features of Microneedles to Modulate Immunity.
Adv Mater. 2023 Dec;35(52):e2302410. doi: 10.1002/adma.202302410. Epub 2023 Nov 5.
4
Tuning innate immune function using microneedles containing multiple classes of toll-like receptor agonists.
Nanoscale. 2023 May 18;15(19):8662-8674. doi: 10.1039/d3nr00333g.
5
Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency.
Acta Pharm Sin B. 2023 Jan;13(1):344-358. doi: 10.1016/j.apsb.2022.04.015. Epub 2022 Apr 29.
6
Application of microneedle patches for drug delivery; doorstep to novel therapies.
J Tissue Eng. 2022 Apr 29;13:20417314221085390. doi: 10.1177/20417314221085390. eCollection 2022 Jan-Dec.
7
Translation of Polymeric Microneedles for Treatment of Human Diseases: Recent Trends, Progress, and Challenges.
Pharmaceutics. 2021 Jul 24;13(8):1132. doi: 10.3390/pharmaceutics13081132.
8
Transdermal approaches to vaccinations in the COVID-19 pandemic era.
Ther Adv Vaccines Immunother. 2021 Aug 21;9:25151355211039073. doi: 10.1177/25151355211039073. eCollection 2021.
本文引用的文献
1
Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.
Vaccine. 2020 Oct 21;38(45):7175-7181. doi: 10.1016/j.vaccine.2020.07.064. Epub 2020 Aug 10.
2
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
PLoS Med. 2020 Mar 17;17(3):e1003024. doi: 10.1371/journal.pmed.1003024. eCollection 2020 Mar.
3
Transdermal delivery of rapamycin with poor water-solubility by dissolving polymeric microneedles for anti-angiogenesis.
J Mater Chem B. 2020 Feb 7;8(5):928-934. doi: 10.1039/c9tb00912d. Epub 2020 Jan 8.
4
Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations.
Adv Exp Med Biol. 2018;1081:371-383. doi: 10.1007/978-981-13-1244-1_20.
5
Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.
Vaccine. 2018 Jan 25;36(4):553-558. doi: 10.1016/j.vaccine.2017.11.083. Epub 2017 Dec 14.
6
Urgent challenges in implementing live attenuated influenza vaccine.
Lancet Infect Dis. 2018 Jan;18(1):e25-e32. doi: 10.1016/S1473-3099(17)30360-2. Epub 2017 Aug 2.
7
Dissolving Microneedle Patches for Dermal Vaccination.
Pharm Res. 2017 Nov;34(11):2223-2240. doi: 10.1007/s11095-017-2223-2. Epub 2017 Jul 17.
8
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27.
9
Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin.
Annu Rev Chem Biomol Eng. 2017 Jun 7;8:177-200. doi: 10.1146/annurev-chembioeng-060816-101514. Epub 2017 Mar 24.
10
Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children.
PLoS One. 2016 Dec 22;11(12):e0169030. doi: 10.1371/journal.pone.0169030. eCollection 2016.
Zotero 插件